Alligator Bioscience Q2 FY26 operating loss widens to SEK 36.2 millionPUBT·Aug 26 at 01:07 AM02696-2.43%
Citi Slightly Raises HENLIUS TP to HKD95.2, Reiterates Buy; Solid Organic Growth in 1H26AASTOCKS News·Aug 25 at 09:55 PM02696-2.43%
Shanghai Henlius files HKEX next-day disclosure return, lifts share capital by 26,600 sharesPUBT·Aug 25 at 05:24 AM02696-2.43%
Shanghai Henlius Biotech to join Hang Seng Composite Index from Sept. 7PUBT·Aug 21 at 06:31 AM02696-2.43%
Shanghai Henlius Biotech IFRS profit rises 10.33% to RMB 430.4 million in H1 FY26; revenue increases 27.3% to RMB 3.59 billionPUBT·Aug 21 at 06:25 AM02696-2.43%
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars PlatformPR Newswire·Aug 16 at 11:08 PMSDZNY-3.02%02696-2.43%
HENLIUS Reaches Global Strategic Partnership With Sandoz, Invoiceable Amt Expected to Reach USD100.5M This YearAASTOCKS News·Aug 16 at 08:06 PM02696-2.43%SDZNY-3.02%
Henlius Strikes Global Biosimilar Alliance with SandozTip Ranks·Aug 16 at 07:09 PM02696-2.43%SDZNY-3.02%
Sandoz partners with Henlius on up to 10 biosimilars in USD 322 million dealPUBT·Aug 16 at 07:00 PMSDZNY-3.02%02696-2.43%
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform | SDZNY Stock NewsStockTitan·Aug 16 at 03:08 PM02696-2.43%SDZNY-3.02%
Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?Simplywall·Aug 9 at 06:33 PM02696-2.43%
Shanghai Henlius says China NMPA clears HLX43-bevacizumab trial in advanced solid tumorsPUBT·Jul 31 at 03:31 AM02696-2.43%
Shanghai Henlius Biotech Grants New Share Options and RSUs to Strengthen IncentivesTip Ranks·Jul 17 at 09:37 AM02696-2.43%
Henlius Doses First Patient in Global Trial of Nivolumab Biosimilar HLX18Tip Ranks·Jul 16 at 03:40 AM02696-2.43%
Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumorsPUBT·Jul 10 at 03:31 AM02696-2.43%
